Schrodinger sees FY24 software revenue growth up 6%-13%

The company sees FY24: “Software revenue growth is expected to range from 6% to 13%. Drug discovery revenue is expected to range from $30 million to $35 million. Software gross margin is expected to be similar to software gross margin for the full year 2023. Operating expense growth in 2024 is expected to range from 8% to 12%. Cash used for operating activities in 2024 is expected to be above cash used for operating activities in 2023. For Q1, software revenue is expected to range from $33 million to $35 million. ”